Learn More
6507 Background: Patients (pts) with R-R ALL have a poor prognosis. CD22 is highly expressed in ALL. IO is active in CD22-positive lymphomas. METHODS Pts with R-R ALL received IO 1.8 mg /m2 IV over(More)
  • 1